Trajectory of Humoral Responses to Two Doses of ChAdOx1 nCoV-19 Vaccination in Patients Receiving Maintenance Hemodialysis-Reference-Cited by-同舟云学术

Trajectory of Humoral Responses to Two Doses of ChAdOx1 nCoV-19 Vaccination in Patients Receiving Maintenance Hemodialysis

Published:2023-04-13 Issue:2 Volume:11 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Ling Tsai-Chieh¹,Chen Po-Lin¹²³,Li Nan-Yao¹,Ko Wen-Chien¹³,Sun Chien-Yao¹⁴,Chao Jo-Yen¹,Shieh Chi-Chang³⁵⁶,Shen Ching-Fen⁵⁶,Wu Jia-Ling¹⁷,Huang Teng-Ching¹,Chao Chiao-Hsuan⁸,Wang Jen-Ren⁸⁹,Chang Yu-Tzu¹^ORCID

Affiliation:

1. Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

2. Infection Control Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

3. Department of Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan

4. Department of Geriatrics and Gerontology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

5. Department of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

6. Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan

7. Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan

8. Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan, Taiwan

9. National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Tainan, Taiwan

Abstract

Patients with kidney failure have worse immune response following vaccination compared to general population, but few clinical studies have investigated immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccination in hemodialysis patients. Here, we showed two doses of AZD1222 vaccines lead to high seroconversion rate of anti-SARS-CoV-2 receptor-binding domain (RBD) antibodies, and more than 80% patients acquired neutralizing antibodies against ancestral virus and delta variant.

Funder

Ministry of Science and Technology, Taiwan

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/spectrum.03445-22

Reference42 articles.

1. Antibody Status, Disease History, and Incidence of SARS-CoV-2 Infection Among Patients on Chronic Dialysis

2. The urgent need to vaccinate dialysis patients against severe acute respiratory syndrome coronavirus 2: a call to action

3. Initial Effects of COVID-19 on Patients with ESKD

4. The Global Impact of the COVID-19 Pandemic on In-Center Hemodialysis Services: An ISN-Dialysis Outcomes Practice Patterns Study Survey

5. Response rates to HB vaccine in CKD stages 3–4 and hemodialysis patients;Ghadiani MH;J Res Med Sci,2012

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 18-month longitudinal SARS COV-2 neutralizing antibody dynamics in haemodialysis patients receiving heterologous 3-dose vaccination (AZD-1222- AZD-1222- BNT162b2) in a lower middle income setting;BMC Nephrology;2024-05-22

2. The development and application of pseudoviruses: assessment of SARS-CoV-2 pseudoviruses;PeerJ;2023-12-06

3. Risk factors and prognosis for coronavirus disease 2019 among 131 hemodialysis patients during the Omicron variant epidemic;Renal Failure;2023-07-28

4. Pre-existing humoral immunity and CD4+ T cell response correlate with cross-reactivity against SARS-CoV-2 Omicron subvariants after heterologous prime-boost vaccination;Clinical Immunology;2023-06